Nav: Home

A surprising new link between inflammation and mental illness

June 14, 2017

Up to 75 percent of patients with systemic lupus erythematosus -- an incurable autoimmune disease commonly known as lupus -- experience neuropsychiatric symptoms. But so far, our understanding of the mechanisms underlying lupus' effects on the brain has remained murky. Now, new research from Boston Children's Hospital has shed light on the mystery and points to a potential new drug for protecting the brain from the neuropsychiatric effects of lupus and other central nervous system (CNS) diseases. The team has published its surprising findings in Nature.

"In general, lupus patients commonly have a broad range of neuropsychiatric symptoms, including anxiety, depression, headaches, seizures, even psychosis," says Allison Bialas, PhD, first author on the study and a research fellow working in the lab of Michael Carroll, PhD, senior author on the study, who are part of the Boston Children's Program in Cellular and Molecular Medicine. "But their cause has not been clear -- for a long time it wasn't even appreciated that these were symptoms of the disease.

Collectively, lupus' neuropsychiatric symptoms are known as central nervous system (CNS) lupus. Carroll's team wondered if changes in the immune system in lupus patients were directly causing these symptoms from a pathological standpoint.

"How does chronic inflammation affect the brain?"

Lupus, which affects at least 1.5 million Americans, causes the immune systems to attack the body's tissues and organs. This causes the body's white blood cells to release type 1 interferon-alpha, a small cytokine protein that acts as a systemic alarm, triggering a cascade of additional immune activity as it binds with receptors in different tissues.

Until now, however, these circulating cytokines were not thought to be able to cross the blood brain barrier, the highly-selective membrane that controls the transfer of materials between circulating blood and the central nervous system (CNS) fluids.

"There had not been any indication that type 1 interferon could get into the brain and set off immune responses there," says Carroll, who is also professor of pediatrics at Harvard Medical School.

So, working with a mouse model of lupus, it was quite unexpected when Carroll's team discovered that enough interferon-alpha did indeed appear to permeate the blood brain barrier to cause changes in the brain. Once across the barrier, it launched microglia -- the immune defense cells of the CNS -- into attack mode on the brain's neuronal synapses. This caused synapses to be lost in the frontal cortex.

"We've found a mechanism that directly links inflammation to mental illness," says Carroll. "This discovery has huge implications for a range of central nervous system diseases."

Blocking inflammation's effects on the brain

The team decided to see if they could reduce synapse loss by administering a drug that blocks interferon-alpha's receptor, called an anti-IFNAR.

Remarkably, they found that anti-IFNAR did seem to have neuro-protective effects in mice with lupus, preventing synapse loss when compared with mice who were not given the drug. What's more, they noticed that mice treated with anti-IFNAR had a reduction in behavioral signs associated with mental illnesses such as anxiety and cognitive defects.

Although further study is needed to determine exactly how interferon-alpha is crossing the blood brain barrier, the team's findings establish a basis for future clinical trials to investigate the effects of anti-IFNAR drugs on CNS lupus and other CNS diseases. One such anti-IFNAR, anifrolumab, is currently being evaluated in a phase 3 human clinical trial for treating other aspects of lupus.

"We've seen microglia dysfunction in other diseases like schizophrenia, and so now this allows us to connect lupus to other CNS diseases," says Bialas. "CNS lupus is not just an undefined cluster of neuropsychiatric symptoms, it's a real disease of the brain -- and it's something that we can potentially treat."

The implications go beyond lupus because inflammation underpins so many diseases and conditions, ranging from Alzheimer's to viral infection to chronic stress.

"Are we all losing synapses, to some varying degree?" Carroll suggests. His team plans to find out.
-end-
This research was supported by the Alliance for Lupus Research (ALR - 332527); the NIH (AI039246, AI42269, AI74549); MedImmune LLC; and the Jeffrey Modell Foundation. In addition to Bialas and Carroll, other authors on the paper included: Jessy Presumey, Abhishek Das, Cornelis van der Poel, Peter H. Lapchak, Luka Mesin, Gabriel Victora, George C. Tsokos, Christian Mawrin and Ronald Herbst.

About Boston Children's Hospital

Boston Children's Hospital, the primary pediatric teaching affiliate of Harvard Medical School, is home to the world's largest research enterprise based at a pediatric medical center. Its discoveries have benefited both children and adults since 1869. Today, more than 2,630 scientists, including nine members of the National Academy of Sciences, 14 members of the National Academy of Medicine and 11 Howard Hughes Medical Investigators comprise Boston Children's research community. Founded as a 20-bed hospital for children, Boston Children's is now a 415-bed comprehensive center for pediatric and adolescent health care. For more, visit our Vector and Thriving blogs and follow us on social media @BostonChildrens,@BCH_Innovation, Facebook and YouTube.

Boston Children's Hospital

Related Lupus Articles:

Studies reveal socioeconomic and racial disparities in lupus
Two new studies have uncovered socioeconomic disparities related to the health of patients with lupus.
Investigating kidney biomarkers to track lupus
To try to better understand how the disease begins and progresses, researchers at the University of Michigan investigated whether kidney biomarkers would signal lupus progression and signs of complications.
Promising new treatment for lupus on the horizon
A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, Monash University-led research published Aug.
Genetic clue to development of mouth ulcers in lupus
Genetic clue to development of mouth ulcers in lupus
Air pollution exposure may worsen lupus in children
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) show for the first time that an individual's exposure to air pollution may have a direct role in triggering disease activity as well as airway inflammation in children and adolescents with systemic lupus erythematosus.
Lupus confirmed as risk factor for cervical cancer
Lupus confirmed as risk factor for cervical cancer
Enzyme keeps antibodies from targeting DNA and driving inflammation in lupus
Failure of an enzyme to break down DNA spilling into the bloodstream as cells die may be a major driver of inflammation in lupus.
Abnormal SHP2 signaling contributes to lupus-like symptoms in mice
In this month's issue of the JCI, a research group led by Maria Kontaridis of Harvard University identifies a link between lupus and elevations in SHP2 activity.
Researchers find new clue in lupus autoantibody production
A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients.
Lupus may contribute to pregnancy-related complications
A new study found that lupus during pregnancy may have negative health impacts for women and their babies.

Related Lupus Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...